Wayne Hwang, MD
Interventional Cardiology · Seattle, WANPI 1205808896
Payments from drug & device makers
Across 21 payments — averaging $130.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Abbott$512
- Boston Scientific$221
- Medtronic$130
- Philips North America LLC$40
- Shockwave Medical, Inc$23
- plus $17 from 1 others
What the payments were for
- Travel & lodging$1,61059%
- Food & beverage$1,12241%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 8 | $1,788 |
| Abbott | 6 | $512 |
| Boston Scientific | 3 | $221 |
| Medtronic | 1 | $130 |
| Philips North America LLC | 1 | $40 |
| Shockwave Medical, Inc | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPIEN 3 Ultra RESILIA$170
- OPTIS$131
- Avalus$130
How this compares
$2,731 in reported general payments places this provider in the 40th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 605 | $776,610 |
| JardianceEmpagliflozin | 244 | $259,467 |
| XareltoRivaroxaban | 156 | $190,008 |
| EntrestoSacubitril/Valsartan | 125 | $150,458 |
| Repatha SureclickEvolocumab | 73 | $75,799 |
| Praluent PenAlirocumab | 37 | $34,248 |
| Repatha SyringeEvolocumab | 28 | $23,573 |
| Metoprolol Succinate | 1,215 | $19,445 |
| FarxigaDapagliflozin Propanediol | 13 | $19,103 |
| BrilintaTicagrelor | 13 | $12,690 |
| Atorvastatin Calcium | 761 | $9,237 |
| Rosuvastatin Calcium | 416 | $7,267 |
| Ezetimibe | 194 | $5,296 |
| Losartan Potassium | 387 | $4,852 |
| ClopidogrelClopidogrel Bisulfate | 270 | $4,778 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Seattle
- Sameer GafoorSeattle$2M
- James McCabeSeattle$1.7M
- William LombardiSeattle$1.2M
- Sidakpal PanaichSeattle$1.2M
- Kathleen KearneySeattle$802K
- Ming ZhangSeattle$693K
- Danny DvirSeattle$380K
- Christopher BrownSeattle$328K
- Lorenzo AzzaliniSeattle$310K
- Christine ChungSeattle$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.